本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SINGAPORE, Dec. 22, 2023 /PRNewswire/ -- After a six-month-long celebration of authentic Spanish cuisine and culture, the Restaurants from Spain campaign, certified by ICEX Spain Trade & Investment, concludes with great success in Singapore. This initiative, aimed at promoting and recognizing restaurants dedicated to delivering exceptional Spanish gastronomic experiences, has captivated the palates of Singaporean food enthusiasts. To date sixteen restaurants have been awarded the Restaurants from Spain certificate, guaranteeing the highest level of quality and authenticity. These restaurants, carefully selected for their commitment to showcasing the rich flavors and traditions of Spanish cuisine, have delighted diners with their exceptional offerings throughout the campaign. Media Campaign with selected media outlets and influencers The campaign has reached out to several key media outlets in Singapore during the past six months to engage their audiences and promote the activities within the Restaurants from Spain communication campaign. We have collaborated with renowned magazines like Epicure, JegGala, Solitare, ExpatLiving and Spirited, to publish sponsored articles promoting our initiatives. Furthermore, we have collaborated with a selected group of influencers and Key Opinion Leaders (KOLs). These include Lady Iron Chef, Rachel Chua, An Affair with Food, Alexis Cheung, Brian Kennett, JohorKaki, Joe Yang, and Sihan Lee, among others. In addition, Spanish Trade Commissioner, Mr. Antonio Garcia Rebollar, was interviewed on OneFM193, where he shared insights about the campaign, and moreover, Kiss 92 FM ran a program dedicated to the Restaurants from Spain campaign. Eat Spain Drink Spain – 15th October – 15th November The Restaurants from Spain participated in the Eat Spain Drink Spain 2023 (ESDS) month of activities designed to introduce Spanish products from importers and encourage visits to the Restaurants. ICEX Spain Trade & Investment organized exclusive tastings and paired dinners catered specifically to professionals in the food and beverage industry. These events provided a unique opportunity for participants to explore and savor the rich flavors of Spanish cuisine while discovering perfect wine pairings. Gaig Restaurant Singapore, renowned for its dedication to preserving Catalan culture and culinary tradition, prepared a special 5-course menu featuring the oldest known recipes from Catalan cuisine, as documented in the historic "Sent Soví" cookbook, the oldest surviving culinary text in Catalan. The renowned restaurants Bolonia and Lumbre organized also special dinners in collaboration with Pares Balta, a family winery with a rich winemaking tradition dating back to 1790. Lumbre is a Spanish restaurant known for sourcing the finest ingredients from land and sea, offered a unique culinary journey with a farm-to-table concept. Diners had the opportunity to indulge in a special dinner and wine pairing experience with Ecolah and Pares Balta, where the flavors of the dishes were complemented by the exquisite wines from Pares Balta's collection. Bolonia is an all-day dining concept inspired by the coastal region in the south of Spain. Located in the heart of Singapore's bustling financial district, Bolonia brings vibrant flavours and relaxed ambiance reminiscent of the Bolonia beach area to Singapore. In addition to these special dinners, the Restaurants from Spain campaign featured a variety of other engaging activities. Una by Diego Grimberg delighted diners with their Monthly Menu, Next Door Spanish Café, in collaboration with Ecolah, offered a delectable Set Lunch menu that highlighted the essence of Spanish cuisine. For wine enthusiasts, The Cricket Club hosted a Spanish Wine Masterclass, providing an educational and immersive experience with Pacific Beverages which featured Estrella de Galicia beer, La Cosecha that brought Spanish wines from Comenge family, and Codorniu which introduced some of their best cavas. Tapas 24 and Tapas Club celebrated the campaign with their respective themed months. Tapas 24 introduced "Spanish Month," during which they offered an array of traditional Spanish tapas and dishes, and the other hand, Tapas Club presented "Cheese Spanish Month," featuring a selection of Spanish cheeses that perfectly complemented their tapas offerings. Also, Pura Brasa and Olivia featured special dishes during the campaign period using some of Ecolah's supplies such as preserved food, canned fish, and seafood products. Olivia, for instance prepared special dishes like clams in spicy green sauce with artichokes and iberico ham, or ensaladilla rusa (Russian salad) or scampi rice Spanish style. At the same time, Vinotecas (wine shops) and gourmet stores hosted special promotions and offers on Spanish food and wines. This initiative created an enticing shopping experience, allowing consumers to explore the wide variety of Spanish products available in the Singaporean market. Beef and Lamb Night at Una by PROVACUNO In light of the recent approval by the Singapore Food Agency (SFA) and the implementation of a new procedure for the export of Spanish beef to Singapore, a special event was held in Singapore in collaboration with PROVACUNO, the Interprofessional Organization for Spanish Beef. The event took place on November 14th at the UNA restaurant, Alkaff Mansion, and welcomed six participating companies in an exclusive gathering attended by key importers and restaurants in the city. Housed at Level 2 of The Alkaff Mansion, UNA pays homage to the age-old heritage of Spanish gastronomy with an innovative and contemporary menu that marries authentic signature delicacies from different regions in Spain. Extracting wholesome and robust flavors through modern cooking techniques, experience the best of Spain through sumptuous tapas, paellas, parrilla grills and more. The main objective of the event was to foster networking among the invited industry professionals, comprising approximately 60 guests, who had the pleasure of enjoying beef provided by PROVACUNO and expertly prepared by renowned Michelin-starred chef, Kisko García. Kisko García represents one of the foremost exponents of Andalusian haute cuisine, a group of avant-garde chefs who continuously infuse their ancient local recipes with imagination. His style, characterized by a strong personality and thoughtful approach, draws inspiration from local ingredients and culinary traditions of Córdoba and the region as a whole. Through extensive training, he pushes boundaries in terms of technique and sensory experiences, creating innovative compositions with remarkable textures and finishes. Dedicated Website & Direct Online Booking for a Spanish Christmas Celebration To enhance accessibility and convenience for customers, the campaign introduced a direct booking dedicated webpage featuring all 16 participating Restaurants from Spain. This centralized hub provided direct booking services to each restaurant, and detailed information about each restaurant, including their specialties and unique offerings, allowing food enthusiasts to explore and book their preferred Spanish dining experiences seamlessly. https://www.restaurantsfromspainsg.com/ Singapore's 16 "Restaurants from Spain": Asador Binomio Esquina FOC Restaurant FOC Sentosa Gaig Kulto Lumbre Next Door Spanish Café Olivia Restaurant & Lounge Pura Brasa Tapas,24 Tapas Club Jewel Tapas Club Orchard Central Tapas Club Vivo City UNA at The Alkaff Mansion
聖誕優惠來嚕！傑昇通信瞄準年末送禮商機，把握機會推出手機限定優惠，限時三天做最後加碼，自即日起至12/24聖誕活動期間，至全台傑昇通信門市購買蘋果指定商品有聖誕便宜價可入手外，三星、ASUS、vivo及OPPO，包含旗艦機款，也祭出各項加碼回饋炒熱買氣，最高都有破萬元的優惠，消費者不妨把握今年最後一檔聖誕優惠。 送禮清單前三名 iPhone 15天天特價 永遠都在送禮清單前三名的蘋果，全台最大連鎖通訊門市─傑昇通信表示，年末適逢送聖誕禮物、企業尾牙挑選禮品犒賞員工之時，尤其是iPhone 15系列新機最受青睞，趁此時到傑昇通信門市換上iPhone 15 Plus（128GB）還能再省3,110元；不僅如此，買氣最好的iPhone 15 Pro Max（256GB）也祭出優惠價40,790元，比原價現省4,110元。熱銷長壽機王iPhone 13（128G）更便宜，只要18,990元。 安卓旗艦機甜甜價 最高降破萬元 想要趁年末優惠入手旗艦機的消費者注意，適逢三星Galaxy S24系列新機即將問世，熱賣全台的三星旗艦機Galaxy S23 Ultra此時價格最甜，聖誕活動期間選購12GB/512GB規格容量，官方定價44,900元，傑昇通信門市價格32,890元，降價幅度相當大，現省逾萬元；全台唯一翻轉鏡頭，用過就回不去的ASUS Zenfone 8 Filp，選擇8GB/256GB規格容量，最低只要12,990元，刷卡再享12期分期0利率。 AirPods Pro第二代 Type-C 加購保護套只要6,790元 同場加映，採用11吋LCD螢幕，功能、效能兼具，在工作通勤或是日常娛樂均可帶來良好體驗的三星平板Galaxy Tab A9+ WiFi（64GB），傑昇通信聖誕優惠期間下殺5,990元；換上Type-C接孔後，還能無損音質的AirPods Pro第二代，充電盒升級至IP54，具備防塵、抗汗及耐水功能，年末耶誕優惠活動期間至傑昇通信門市購買，加購保護套就能用6,790元帶回家。 此外，性價比高的平價機型，也一直是小資族換機首選，有超大儲存容量的vivo Y36，續航還有5,000mAh電池，支援44W快充，影像性能方面，前置相機畫素1,600萬畫素，官方萬元有找的定價，傑昇通信聖誕優惠直降66折；年末想犒賞辛苦一整年的自己，推薦採用聯發科天璣7050處理器的OPPO Reno10，一樣有5,000mAh大電量、支援67W快充，傑昇通信聖誕優惠破盤65折。
NANJING, China, Dec. 20, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit® linker-payload platform from Escugen for the development of the next generation tumor-associated antigens (TAAs) targeting ADCs. The license agreement provides InxMed with right to use EZWi-Fit® platform on the several novel ADC candidate molecules. InxMed will have the right for development, manufacturing, and commercialization of these ADC candidate molecules. InxMed is developing next generation TAAs targeting ADCs with significant improvement of efficacy and therapeutic window. Meanwhile, the company is developing solutions to boost ADC's efficacy including enhancing ADC penetration via FAK inhibitor and developing stroma targeting ADC to create synergy. InxMed is positioned to invent next generation ADCs, with the attributes to be more tumor selective and potent, and broad combination potential. The novel antibodies discovered by InxMed to be equipped with payload from EZWi-Fit®platform will be one of key differentiations. About InxMed InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies against tumor resistance and metastasis. InxMed is committed to build an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology. InxMed has translational medicine and clinical teams at Nanjing，Shanghai and Beijing in China, and has team members located in the United States, Canada and Australia. Through its own discovery research and development, and collaborative research and development, InxMed has built a highly differentiated, and intrinsic synergistic pipeline. InxMed has completed several rounds of financing totaling more than 100 million US dollars raised. Its first developing drug, IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), received Fast-track Designation from the U.S. Food and Drug Administration and Breakthrough Therapy Designation from the China National Medical Products Administration against platin resistant ovarian cancer. The pivotal clinical trial is ongoing. About EZWi-Fit® EZWi-Fit® is the State-of-the-Art ADC platform technology invented by Escugen with the global IP rights. It couples a potent Topoisomerase I inhibitor with high and homogeneous drug-antibody ratio (DAR) to the antibody with a stable cleavable linker. The proprietary chemical modification of the linker not only confers the conjugates with excellent hydrophilicity, but also minimizes the de-conjugation of the linker-payload. Outstanding Pharmacokinetic features so derived provides ADC with substantial in vivo efficacy, which is superior to that of GGFG-Dxd ADC in multiple CDX and PDX models, involving different targets and antibodies. Great By-stander Effect of the linker-payload warrants specific and significant efficacy in various low affluence and high heterogenicity target expressing tumor models, which is even resistance to MMAE and Dxd ADC. The EZWi-Fit® derived ADC is well tolerated in the Non-Human Primate toxicology studies, without reaching the Maximum Tolerable Dose (MTD) at 60-80 mg/kg. With this edge-cutting technology, Escugen is quickly expanding the Frist-in-Class ADC pipeline to satisfy the unmet medical needs. About Escugen Escugen was founded in 2017，focusing on the development of innovative Antibody Drug Conjugates (ADC) for cancer therapy. The founders of Escugen are veterans of biotech industry, with rich working experience gained in the leading companies of both China and the US. The expertise of its research team covers antibody discovery, bio-conjugation, process development, quality research, preclinical and clinical studies. The most advanced project, ESG401, currently in PhIb/II clinical trials, is a TROP-2 ADC that uses an innovative stable cleavable linker designed for significant reduction of the off-target toxicity. Topoisomerase I inhibitor is the payload, with the Drug-Antibody Ratio (DAR) at 8 homogeneously. Clinical data shows that the tolerable dose of ESG401 is remarkably greater than that of other ADCs to the same target. The incidence of the Off-target toxicity, such as neutropenia, is low and mild, and no diarrhea greater than Grade 3 has been reported. The On-target Off-tumor toxicity, such as stomatitis, was rare. In the patients with heavily treated metastatic triple-negative and HR+/Her-2- breast cancer, promising evidence of efficacy has been observed, including the regression of the visceral and intracranial metastatic lesions.
Exchanging the latest research findings to promote cross-regional cooperation and stop discriminationHONG KONG SAR - Media OutReach Newswire - 4 December 2023 - Every year, on 1 December, the world commemorates World AIDS Day. People around the world unite to show support for people living with HIV. The 7th AIDS Forum of Beijing, Hong Kong, Macau & Taiwan was held from December 4th to 5th, 2023, and successfully kicked off on the first day. On the opening day, Mr. John Lee Ka-chiu, the Chief Executive of the Hong Kong Special Administrative Region, congratulatory message via video and said that only by creating a friendly and non-discriminatory social environment can people suspected of being infected be encouraged to get tested for the virus as early as possible. Only in this way to help people living with HIV have the courage to receive treatment as early as possible. The number of new HIV infection cases in Hong Kong has also been showing a downward trend in the past seven years. Join hands to move towards the goal of "ending AIDS as a threat to public health by 2030" advocated by the United Nations Program on AIDS. Left to right: Dr. LEONG Iek Hou Head of Centre for Disease Control and Prevention, Health Bureau, Macao SAR; Mr. HAN Mengjie, Chief expert on AIDS Prevention and Control of the Chinese Center for Disease Control and Prevention; Professor SHANG Hong, Academician of China Academy of Engineering, Director of the First Hospital of China Medical University; Dr. Erasmus U. MORAH，Director and Representative, UNAIDS China Office; Dr. Margaret CHAN, Dean of Vanke School of Public Health, Tsinghua University; Dr Che Hung LEONG, the Chairman of Hong Kong AIDS Foundation; Mr Chen Zetao, the Deputy Director-General of the Co-ordination Department of the Liaison Office of the Central People's Government in the Hong Kong Special Administrative Region; Dr LEE Ha-yun, Libby, JP, Under Secretary for Health to share her message; Professor David HO, Director of the Aaron Diamond AIDS Research Center; Mr. HAO Yang, President of Chinese Association of STD & AIDS Prevention and Control; Ms. WANG Xinlun, Vice-President of Chinese Association of STD & AIDS Prevention and Control; Dr. JIN Ronghua, Director of National Center for Infectious Diseases (Beijing), President of the Beijing Ditan Hospital; Dr. Chien-Chin HUNG, President of Taiwan AIDS Society; Professor CHEN Zhiwei, Director of AIDS Institute, Chair Professor, Department of Microbiology, LKS Faculty of Medicine, the University of Hong Kong All honourable guests participated in the opening ceremony, wishing that parties from the 4 regions could continue to collaborate closely in AIDS management through sharing new research findings and achievements in the Forum. Over a hundred experts and representatives from non-governmental organizations also attend the two-day Forum and share the unique experiences, hoping to enhance the prevention strategies for AIDS and reshape society's perception of AIDS issues. Website of The 7th AIDS Forum of Beijing, Hong Kong, Macau & Taiwan: https://aids.org.hk/the7thaidsforum The AIDS Forum has been co-hosted by four prominent and leading HIV/AIDS-related NGO every two years in various hosting cities since 2010. This year, the Forum will be hosted by the Hong Kong AIDS Foundation along with substantial support from counterparts from the Mainland China, Macau and Taiwan and is themed " together, we create a stigma-free world". It aims to promote collaboration among researchers, medical expertise, and non-governmental organizations. In addition to the strong support from Mainland China, Macau, and Taiwan, government officials, including Mr. Chen Zetao, the Deputy Director-General of the Co-ordination Department of the Liaison Office of the Central People's Government in the Hong Kong Special Administrative Region, Dr LEE Ha-yun, Libby, JP, Under Secretary for Health, Dr. Margaret Chan Fung Fu-chun, the Dean of Vanke School of Public Health, Tsinghua University, Professor David HO, Director of the Aaron Diamond AIDS Research Center and Dr. LEONG Iek Hou, the Head of Center for Disease Control and Prevention, Health Bureau, Macao SAR, also attended the opening ceremony. Dr. Che Hung Leong, the Chairman of the Hong Kong AIDS Foundation, delivered a welcome speech, highlighting the aspirations behind this year's slogan, " together, we create a stigma-free world". He said that AIDS is not only a medical problem, but also a social problem. In the past, he has been committed to going into the community to educate the public on prevention, especially the importance of safe sex. Finally, we also call on our respective governments to continue their efforts in the fight against HIV/AIDS. Over a hundred representatives and medical expertise attended to discuss the current AIDS situation in the four regions. The Forum was divided into eight sessions, addressing the situation, treatment, prevention of AIDS, as well as the support services in the four regions. Support for people living with HIV, including the HIV Care Continuum & Beyond White Paper and the challenges of promoting PrEP in Asia. Roundtable discussions further explored opportunities for cross-regional cooperation in AIDS prevention and how various entities can prevent and control the virus. Each session involved representatives and leading minds in the medical field from the four regions who shared their experiences, aiming to strengthen the cooperation among related medical institutions, disease prevention and control centres, non-governmental organizations, and other social workers in the region. Professor David Ho, the Director of Aaron Diamond AIDS Research Center announced the Global AIDS Response Strategy Professor David Ho, the Director of Aaron Diamond AIDS Research Center shared insights from his decades-long personal journey fighting the global AIDS pandemic. Professor David Ho unravelled the dynamic nature of HIV replication in vivo and revolutionized our basic understanding of this horrific disease. This knowledge led him to champion combination antiretroviral therapy (cocktail therapy) that resulted in unprecedented control of HIV in patients. An automatic death sentence has been transformed into a manageable disease, and near 30 million worldwide are currently on such therapy. As one of the main founders of the 'Pandemic Research Alliance', his initiatives provide transformative solutions and contribute to the well-being of humanity. Professor Chen Zhiwei, the Director of AIDS Institute and the Chair Professor, Department of Microbiology, LKS Faculty of Medicine, The University of Hong Kong announced the development of AIDS vaccine. Meanwhile, Professor Chen Zhiwei, the Director of AIDS Institute and the Chair Professor, Department of Microbiology, LKS Faculty of Medicine, The University of Hong Kong announced the development of HIV vaccine during the Forum. He also discussed the current status of immunotherapy for curing HIV. Professor Chen has been actively participating in vaccine design and development, thus promoting cross-region collaboration in the field of public health. Echoing UNAIDS' current target, all parties join hands to achieve zero discrimination and improve the quality of life for people living with HIV/AIDS. The forum also focused on the treatment of patients, echoing UNAIDS' current target: 95% of people with HIV who know their status will be on treatment and 95% of people with HIV on treatment will be virally suppressed by 2025. Through the implementation of online health support services and adhered to its philosophy of "People-centric", the Forum aim to re-boost the early realization of "zero new HIV infections, zero AIDS-related deaths and zero HIV-related stigma and discrimination by 2030" through the Forum particularly after the end of COVID pandemic. The issuer is solely responsible for the content of this announcement.About Hong Kong AIDS FoundationHong Kong AIDS Foundation was established in 1991. Prompted by the general public's poor understanding of AIDS and common misconceptions about those living with HIV/AIDS, a group of people coming from different sectors of society who cared for the betterment of the community joined together to form Hong Kong AIDS Foundation, a non-governmental social service organization, to curb the spread of HIV/AIDS in Hong Kong. To learn more about Hong Kong AIDS Foundation, please visit: Website: https://www.aids.org.hk/ Facebook：https://www.facebook.com/hongkongaidsfoundationofficial Instagram：https://www.instagram.com/hkaidsfoundation/
SOUTH SAN FRANCISCO, Calif., Dec. 1, 2023 /PRNewswire/ -- 280Bio, Inc., a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the first patient was treated with TEB-17231 (YL-17231), a small molecule inhibitor of RAS signaling. 280Bio is a wholly owned subsidiary of Shanghai Yingli Pharmaceuticals, Inc. (Yingli Pharma) of Shanghai, China. KRAS, NRAS and HRAS genes are frequently mutated in many tumor indications causally associated with promoting tumor cell growth. TEB-17231 demonstrated potent inhibition of tumor cell proliferation in vitro and in vivo in preclinical research, exhibiting activity with different KRAS, NRAS and HRAS alterations, including tumors that have become resistant to KRAS G12C inhibitors. "We are gratified that the first patient has been dosed with our novel pan-RAS inhibitor, marking a major step in TEB-17231's clinical development, and introducing new medicines for the patients we hope to serve." said Michael Hui, Chief Executive Officer of 280Bio Inc., "This milestone highlights our commitment to addressing unmet needs in cancers through precision oncology approaches. We look forward to continued enrollment and dosing of patients in this trial." This first US patient was enrolled at The University of Texas MD Anderson Cancer Center, Houston, Texas, by David Hong, MD, Deputy Chair of Investigational Cancer Therapeutics and lead investigator on the trial. Reflecting on the high unmet need for new cancer agents, Dr. Zusheng Xu, Head of Research and Development of Yingli Pharma, said "TEB-17231 was developed to have a broader activity against the oncogenic RAS signaling pathways, than is currently demonstrated for many of the KRAS inhibitors. With its excellent pharmacologic and in vivo anti-tumor properties, we are hopeful that TEB-17231 will also be determined to be safe and efficacious by continuous oral dosing in patients." About 280Bio 280Bio, headquartered in the San Francisco Bay Area, is developing innovative precision small molecule inhibitors for the treatment of cancer. 280Bio is a wholly owned subsidiary of Shanghai Yingli Pharmaceutical Co., Ltd., Shanghai, China (Yingli Pharma), with an oncology pipeline that is leveraging the strong medicinal chemistry and pharmacology capabilities of the company. 280Bio focuses on oral agents directed against frequently mutated genetic changes and well-validated genetic instability features of many cancers. TEB-17231 is part of a strategic collaboration of 280Bio with The University of Texas MD Anderson Cancer Center, where further preclinical research of the investigational drug is continuing. The collaboration also is currently advancing clinical development in the U.S./E.U. of two other drugs, linpersilib (PI3Kδ inhibitor from Yingli Pharma, approved in China in 2022) in a T-cell lymphoma Phase 2 trial, and YL-13027 (TGFβR1 inhibitor from Yingli Pharma) in a Phase 1 dose escalation study.
根據市調機構最新調查結果，2023年10月台灣實體通路智慧手機市場銷售量共賣出逾53萬台，不僅較上月挹注9.1萬台，銷售額再成長21%，整體成績穩定成長；進一步觀察手機品牌銷售佔比排名，傑昇通信表示，iPhone 15系列新機轟炸全台，蘋果以52.9%過半的市占率，持續蟬聯第一，也是最接近疫情前水準的一次，其他品牌表現像是三星市占率則以20%排名第二，OPPO則是8.7%，vivo及紅米市占分別為5%與4.4%。 果粉好給力 半數人全買iPhone 全台最大連鎖通訊門市─傑昇通信分析手機品牌市占前五名的銷量與銷售額，10月整體手機市場受惠蘋果iPhone 15新機上市，不僅蘋果本月52.9%的市占率過半，品牌整體銷量也較上月增加34%，更因單機單價提高，銷售額更成長四成。進一步比對去年同期，較iPhone 14上市時銷量略減2%，傑昇通信坦言與Pro以上旗艦系列開賣首月到貨量少，造成市場缺貨關係直接。 本月蘋果的前三名單機，皆為規格有感提升的iPhone 15系列，像是充電接口全系列改為USB-C、導入獨有的動態島介面，以及首次導入潛望鏡頭的iPhone 15 Pro Max，也是到貨時間最長的機型，仍不減果粉對其熱愛，傑昇通信認為，智慧手機市場尚未度過景氣寒冬，但果粉推升的換機潮仍令第一波上市買氣大好，預期旗艦機的買氣有望持續到年底。 三星A系列突圍 A54銷量漲3成大贏iPhone 本月市占排名第二的三星，十月市占率20%，與上月22.8%相比，銷量也有5%的成長，傑昇通信觀察，榜上前三名機型都是熱賣的A系列，像是Galaxy A54（8GB/256GB）及A14（4GB/64GB）及A34（6GB/128GB）；值得注意的是，Galaxy A54（8GB/256GB）不僅是安卓陣營唯一賣贏iPhone的單機，本月單機銷量更提升逾3成，顯見不僅規格不俗的A系列中階機型，現階段通路價格幾乎萬元有找，難怪人氣依舊居高不下。 vivo倒吃甘蔗 銷量及銷售額雙雙看漲 越接近年底，各手機大廠推陳出新、競爭激烈，傑昇通信發現另一個倒吃甘蔗的品牌，則是市占率5%，排行第四的vivo，前三名單機都是價格親民的Y系列，規格更勝其他品牌同級機型，帶動整體銷量成長15%，銷售額更大增38%，僅次蘋果，低調且驚人的成長速度，令人刮目相看；市占率8.7%排名第三的OPPO，品牌前三名機型與上月大致相符，熱賣的OPPO Reno10 Pro單機銷量也有6%的提升，算是TOP 5中影響較小的品牌。
A12 藝術空間
vivo
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
